Matelis Quoted in Law360 About SEC Disclosure Requirements Avenatti Extortion Case Against Nike
28 March 2019
Law360
Partner Jessica Matelis was quoted in the Law360 article, ‘Geragos ‘Chargeable’ in Avenatti Extortion Case, Experts Say.”
Matelis responded to questions of whether Nike needed to disclose in SEC filings that it was cooperating with authorities in an investigation into alleged corruption with college basketball players. Celebrity lawyers Michael Avenatti and Mark Geragos have been accused of trying to extort money from the shoemaker in connection with the alleged corruption.
Matelis told Law360 that there is no bright-line rule as to when a company needs to disclose that it is cooperating in an investigation. “It could very well be that the company was told by criminal authorities not to disclose anything,” she said.
Matelis responded to questions of whether Nike needed to disclose in SEC filings that it was cooperating with authorities in an investigation into alleged corruption with college basketball players. Celebrity lawyers Michael Avenatti and Mark Geragos have been accused of trying to extort money from the shoemaker in connection with the alleged corruption.
Matelis told Law360 that there is no bright-line rule as to when a company needs to disclose that it is cooperating in an investigation. “It could very well be that the company was told by criminal authorities not to disclose anything,” she said.
Related News
10 October 2024
In the News
Christopher King Highlights M&A Due Diligence Considerations
Foley & Lardner LLP partner Christopher King's comments on M&A due diligence at the Association of Corporate Counsel's annual meeting were highlighted in the Legal Dive article, "Can this marriage work? Legal tips for corporate M&A."
09 October 2024
In the News
Jason Mehta Weighs in on SEC Settlements, Clinical Research Fraud
Foley & Lardner LLP partner Jason Mehta commented on a recent health care litigation settlement with the U.S. Securities and Exchange Commission in the Clinical Trials Arena article, “Cassava Sciences: Phase III trials storm ahead amid controversy.”
08 October 2024
In the News
John Strom Assesses BIOSECURE ACT – 'Going to be tough to navigate'
Foley & Lardner LLP special counsel John Strom shared insight on the potential impact of the BIOSECURE ACT in the BioSpaces article, "WuXi Biologics Faces Uncertain Future in the U.S. After BIOSECURE Blow."